The Aviragen Therapeutics, Inc. (AVIR) Given $4.50 Average Target Price by Brokerages

The Aviragen Therapeutics, Inc. (AVIR) Given $4.50 Average Target Price by Brokerages

Shares of Aviragen Therapeutics, Inc. (NASDAQ:AVIR) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokers have set a twelve-month consensus target price of $4.50 for the company and are expecting that the company will post ($0.18) EPS for the current quarter, according to Zacks. Zacks has also given Aviragen Therapeutics an industry rank of 90 out of 265 based on the ratings given to related companies.

A number of brokerages have issued reports on AVIR. FBR & Co reiterated a “buy” rating on shares of Aviragen Therapeutics in a research note on Monday, November 7th. Ladenburg Thalmann began coverage on shares of Aviragen Therapeutics in a research note on Wednesday, September 21st. They set a “buy” rating on the stock.

Aviragen Therapeutics (NASDAQ:AVIR) opened at 1.39 on Monday. Aviragen Therapeutics has a 12 month low of $1.14 and a 12 month high of $2.00. The stock’s market capitalization is $53.71 million. The company has a 50 day moving average of $1.28 and a 200 day moving average of $1.40.

Several institutional investors have recently made changes to their positions in the company. Eagle Global Advisors LLC bought a new position in shares of Aviragen Therapeutics during the second quarter worth approximately $381,000. Bridgeway Capital Management Inc. bought a new position in shares of Aviragen Therapeutics during the second quarter worth approximately $300,000. Senzar Asset Management LLC bought a new position in shares of Aviragen Therapeutics during the second quarter worth approximately $2,848,000. FMR LLC bought a new position in shares of Aviragen Therapeutics during the second quarter worth approximately $420,000. Finally, BlackRock Institutional Trust Company N.A. bought a new position in shares of Aviragen Therapeutics during the second quarter worth approximately $691,000. 33.77% of the stock is owned by institutional investors and hedge funds.

About Aviragen Therapeutics

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.

Get a free copy of the Zacks research report on Aviragen Therapeutics (AVIR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment